Companies › Kangabio AUSTRALIA
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KGX101 Heterodimeric IL-12 prodrug with masked N-terminus and ADCC-impaired IgG1 Fc fusion | IL12, IL12RB1, IL12RB2 | Phase 1 | Advanced or Metastatic Solid Tumors | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07260305 | KGX101 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Jan 2027 |
| NCT06074497 | KGX101 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | May 2028 |
Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics enGene Inovio Pharmaceuticals Trogenix
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.